Disrupting ALDH1A3 expression in VSMCs can halt the progression of hypoxia-driven PAH by reducing glycolytic activity, thus preventing the phenotypic shift in VSMCs (74). The gene discussed is ALDH1A3; the disease is pulmonary arterial hypertension.